Lotte Biologics signs antibody drug CMO deal with UK’s Ottimo Pharma
BOSTON – Lotte Biologics Co. has signed a deal to manufacture an antibody therapy for British biotech startup Ottimo Pharma as the South Korea...
Samsung Biologics to spin off biosimilar unit Samsung Bioepis
Samsung Biologics Co., the world’s largest contract drugmaker, will undergo a strategic split to separate its contract development and manufac...
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
China bans export of Korean goods containing its rare earth metals to US
The Chinese government has warned South Korean companies of retributions for exporting any product containing its critical metals to US military con...
Celltrion expands footprint in Latin America with flagship oncology drugs
South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...
With domestic dockyards fully booked, Korean shipbuilders turn overseas
As order books swell amid green shipping mandates, LNG demand and military naval modernization, South Korean shipbuilders are extending their global...
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Samsung's Lee meets with Xi amid Beijing’s balancing act vs Washington
Samsung Electronics Co. Chairman Lee Jae-yong, along with other global tech leaders, met with Chinese President Xi Jinping in Beijing on Friday as C...
Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US
South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...
SillaJen: First to use lab-grown human tissue to find best cancer drug dose
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...
Chong Kun Dang to build new plant for foray into biologics market
Chong Kun Dang Pharmaceutical Corp. is discussing building a research center and a plant in Siheung, about 30 kilometers southwest of Seoul, with th...
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
China likely to lift ban on South Korea’s K-wave as early as May
BEIJING – China will likely lift its ban on Hallyu, or Korean popular culture in the country, as early as May, moving away from its “wol...
Hanmi Semiconductor to retire $90 mn treasury shares in May
Hanmi Semiconductor Co. on Thursday announced a plan to retire 130.0 billion won ($90 million) worth of treasury shares in May, marking its largest-...
Lotte Biologics eyes first ADC CDMO order in 2025
SAN FRANCISCO -- Lotte Biologics Co., the drug consignment development and production unit of South Korean conglomerate Lotte Group, will seek to wi...
Celltrion seeks large-scale M&A in Q4, eyes 2027 Nasdaq debut
SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as...
SK Biopharmaceuticals, Eurofarma to set up AI epilepsy platform JV in US
South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture ...
Hanmi Semiconductor to build new TC Bonder plant in Incheon
Hanmi Semiconductor Co., South Korea’s leading chip packaging equipment manufacturer, held a ground-breaking ceremony for its seventh plant of...
Yuhan’s lung cancer drug gets OK in Europe
Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...
Hanmi Pharm’s chair poised to win management feud with her son
Hanmi Pharmaceutical Group Chairman Song Young-sook is poised to claim victory in a year-long dispute with her eldest son Lim Jong-yoon to take cont...
Boryung, Lotus Pharma signs CDMO deal on anticancer injection
South Korea's Boryung Corp. said on Thursday it signed a contract with Lotus Pharmaceutical, a Taiwanese oncology firm, for contract development and...
Hanmi breaks ground pharmaceuticals complex in Beijing
South Korea's Hanmi Pharmaceutical Co. said on Friday that Beijing Hanmi Pharm, its subsidiary in China, held the groundbreaking ceremony for a proj...
SK Biopharm submits NDA of epilepsy drug to China
South Korea's SK Biopharmaceuticals Co. said on Tuesday it submitted the new drug application (NDA) for its flagship epilepsy drug Cenobamate to Chi...
La Defense might have a say over Hanmi Pharm's family feud
La Defense Partners is expected to exercise a casting vote over the ongoing management dispute at Hanmi Science Co. after the Seoul-based private eq...
Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug
Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...
Hanmi Pharma to move up launch of anti-obesity drug
South Korea’s Hanmi Pharmaceutical Co. announced on Thursday the launch of its anti-obesity drug candidate efpeglenatide has been rescheduled ...
Samsung Biologics wins $668 million CDMO deal with European pharma
Samsung Biologics Co., the world’s largest contract drugmaker, said on Wednesday it has signed two drug manufacturing contracts worth a combin...
Hanmi Bank rises from Koreatown lender to regional bank
It began in 1982 as a small community bank for Korean immigrants in Los Angeles, California. Today, Hanmi Bank, under Nasdaq-listed Hanmi Financial ...
Celltrion's anti cancer drugs hold 90% market share in C.America
South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....
Yuhan’s lung cancer drug clears FDA hurdle for global debut
A new lung cancer treatment developed by South Korea’s Yuhan Corp. has secured approval from the US Food and Drug Administration (FDA) as a co...
